Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma

Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma

Martina Lehnert, Heinz Ludwig, Niklas Zojer 1st Department of Medicine, Center for Oncology and Hematology, Wilhelminenspital, Vienna, AustriaAbstract: The development of radiolabeled antibodies against CD20 has facilitated targeted treatment of follicular lymphoma (FL). By using 90Y-ibritumomab tiu...

Full description

Bibliographic Details
Main Authors: Martina Lehnert, Heinz Ludwig, Niklas Zojer
Format: Article
Language:English
Published: Dove Medical Press 2009-07-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/update-on-the-rational-use-of-90y-ibritumomab-tiuxetan-in-the-treatmen-a3399

Similar Items

Similar Items